Secondary malignant neoplasm of genital organs
ICD-10 C79.82 is a billable code used to indicate a diagnosis of secondary malignant neoplasm of genital organs.
C79.82 refers to secondary malignant neoplasms that have metastasized to the genital organs from a primary site elsewhere in the body. This condition indicates that cancer cells have spread to the genital organs, which may include the ovaries, uterus, vagina, penis, or testicles. The primary tumor may be of unknown origin, complicating diagnosis and treatment. Metastatic disease in the genital organs can lead to various symptoms, including pain, abnormal bleeding, and changes in urinary or sexual function. Staging of the disease is crucial for determining the extent of metastasis and guiding treatment options. Palliative care considerations are essential for managing symptoms and improving the quality of life for patients with advanced disease. Treatment may involve chemotherapy, radiation therapy, or surgical interventions, depending on the primary cancer type and the extent of metastasis. Accurate coding is vital for appropriate reimbursement and tracking of cancer treatment outcomes.
Detailed history of the primary cancer, staging information, and treatment plans.
Patients presenting with symptoms of metastasis to genital organs, such as pelvic pain or abnormal bleeding.
Ensure accurate documentation of the primary site and any previous treatments.
Comprehensive assessment of symptoms, treatment goals, and patient preferences.
Patients with advanced metastatic disease requiring symptom management.
Focus on quality of life and symptom relief, which may influence coding.
Used during follow-up visits for patients with metastatic disease.
Document the patient's history, examination findings, and treatment plan.
Oncology specialists should ensure comprehensive documentation of cancer history.
Coding C79.82 is crucial for accurately representing metastatic disease in the genital organs, which impacts treatment planning, reimbursement, and cancer registry data.
